TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FOR
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter8h01:8hDrug8hDefinitions,8hStandards,8hand8hInformation8hSources8hWillihn
ganz:8hClayton’s8hBasic8hPharmacology8hfor8hNurses,8h19th8hEdition
MULTIPLE8hCHOIC
E
1. Which8hname8hidentifies8ha8hdrug8hlisted8hby8hthe8hUS8hFoo
d8hand8hDrug8hAdministration8h(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:8h C
The8hofficial8hname8his8hthe8 h name8hunder8hwhich8ha8hdrug8his8
hlisted8hby8hthe8hFDA.8hThe8hbrand8hname,8hor8htrademark,8his8ht
he8hname8hgiven8hto8ha8hdrug8hby8hits8hmanufacturer.8hThe8hnon
proprietary,8hor8hgeneric,8hname8his8hprovided8hby8hthe8hUnited
8hStates8hAdopted8hNames8hCouncil.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h9
OBJ:8h1NAT:8hNCLEX8hClient8hNeeds8hCategory:8hSafe,8hEffective
8hCare8hEnvironment8hTOP:8 h Nursing8hProcess8hStep:8hAssessment
CON:8
hPatient8hEducation
2. Which8hsource8hcontains8hinformation8hspecific8hto8hnutritional8hsupplements?
a. USP8hDictionary8hof8hUSAN8h &8hInternational8hDrug8hNames
b. Natural8hMedicines8hComprehensive8hDatabase
c. United8hStates8hPharmacopoeia/National8hFormulary8h(USP8hNF)
d. Drug8hInteraction8hFacts
ANS:8h C
United8hStates8hPharmacopoeia/National8hFormulary8hcontains8hinformation8hspecific8hto8hnutriti
onal8hsupplements.8hUSP8hDictionary8hof8hUSAN8h&8hInternational8hDrug8hNames8his8ha8hcompilat
ion8hof8hdrug8hnames,8hpronunciation8hguide,8hand8hpossible8hfuture8hFDA8happroved8hdrugs;8hit8hd
oes8hnot8hinclude8hnutritional8hsupplements.8hNatural8hMedicines8hComprehensive8hDatabase8hc
ontains
evidence-
based8hinformation8hon8hherbal8hmedicines8hand8hherbal8hcombination8hproducts;8hit8hdoes8hnot8hincl
ude8hinformation8hspecific8hto8hnutritional8hsupplements.8hDrug8hInteraction8hFacts8hcontains8hco
mprehensive8hinformation8hon8hdrug8hinteraction8hfacts;8hit8hdoes8hnot8hinclude8hnutritional8hsupp
lements.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h4
OBJ:8h38hNAT:8 h NCLEX8hClient8hNeeds8hCategory:8hPhysiological8
hIntegrity
TOP:8 h Nursing8hProcess8hStep:8hAssessment CON:8 h Nutrition8h|8hPatient8hEducation
3. Which8hdrug8hreference8hcontains8hdrug8hmonographs8hthat8hdescribe8hall8hdrugs8hin8ha8htherapeutic8hclass?
a. Drug8hFacts8hand8hComparisons
,Test8hBank8hFor8hClayton’s8hBasic8hPharmacology8hfor8hNurses8h19th8 3
hEdition
b. Drug8hInteraction8hFacts
c. Handbook8hon8hInjectable8hDrugs
d. Martindale—The8hComplete8hDrug8hReference
ANS:8 h A
Drug8hFacts8hand8hComparisons8hcontains8hdrug8hmonographs8hthat8hdescribe8hall8hdrug
s8hin8ha8htherapeutic8hclass.8hMonographs8hare8hformatted8has8htables8hto8hallow8hcompariso
n8hof8hsimilar8ph roducts,8hbrand8hnames,8hmanufacturers,8hcost8hindices,8hand8havailable8hd
osage8hforms8hOnline8hversion8his8havailable.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h48hTable8h1.2
OBJ:8h8h8 h 3 NAT:8 h NCLEX8hClient8hNeeds8hCategory:8hPhysiological8hIntegrity
TOP:8 h Nursing8hProcess8hStep:8hAssessment CON:8 h Safety8h|8hPatient8hEducation8h|8hClinical8hJudgment
4. Which8hdrug8hreference8hcontains8hmonographs8habout8h virtually8hevery8hsingle-
entity8hdrug8havailable8hin8hthe8hUnited8hStates8hand8hdescribes8htherapeutic8huses8hof8hdrugs,8hincl
uding8happroved8hand8hunapproved8huses?
a. Martindale:8hThe8hComplete8hDrug8hReference
b. AHFS8hDrug8hInformation
c. Drug8hReference
d. Drug8hFacts8hand8hComparisons
ANS:8 h B
AHFS8hDrug8hInformation8hcontains8hmonographs8habout8hvirtually8hevery8hsingle-
entity8hdrug8havailable8hin8hthe8hUnited8hStates8hand8hdescribes8htherapeutic8huses8hof8hdrugs,8hinclu
ding8happroved8hand8hunapproved8huses.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h48hTable8h1.2
OBJ:8h8h8 h 3 NAT:8 h NCLEX8hClient8hNeeds8hCategory:8hPhysiological8hIntegrity
TOP:8 h Nursing8hProcess8hStep:8hPlanning CON:8 h Safety8h|8hPatient8hEducation8h|8hClinical8hJudgment
5. Which8honline8hdrug8hreference8hmakes8havailable8hto8hhealthcare8hproviders8hand8hthe8hpubli
c8ha8hstandard,8hcomprehensive,8hup-to-
date8hlook8hup8hand8hdownloadable8hresource8habout8hmedicines?
a. American8hDrug8hIndex
b. American8hHospital8hFormulary
c. DailyMed
d. Drug8hReference
ANS:8h C
DailyMed8hmakes8havailable8hto8hhealthcare8hproviders8hand8hthe8hpublic8ha8hstandard,8hcomprehe
nsive,8hup-to-
date8hlook8hup8hand8hdownloadable8hresource8habout8hmedicines.8hThe8hAmerican8hDrug8hIndex8hi
s8hnot8happropriate8hfor8hpatient8huse.8hThe8hAmerican8hHospital8hFormulary8his8hnot8happropriate
8hfor8hpatient8h use.8hThe8hdrug8hreference8h is8hnot8happropriate8hfor8hpatient8h use.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h38h|8hp.8h4
OBJ:8h38hNAT:8 h NCLEX8hClient8hNeeds8hCategory:8hPhysiological8
hIntegrity
TOP:8 h Nursing8hProcess8hStep:8hImplementation
CON:8 h Safety8h|8hPatient8hEducation8h|8hClinical8hJudgment
6. Which8hlegislation8hauthorizes8hthe8hFDA8hto8hdetermine8hthe8hsafety8hof8ha8hdrug8hbefore8hits8hmarketing?
a. Federal8hFood,8hDrug,8hand8hCosmetic8hAct8h(1938)
b. Durham8hHumphrey8hAmendment8h(1952)
, Test8hBank8hFor8hClayton’s8hBasic8hPharmacology8hfor8hNurses8h19th8 4
hEdition
c. Controlled8hSubstances8hAct8h(1970)
d. Kefauver8hHarris8hDrug8hAmendment8h(1962)
ANS:8 h A
The8hFederal8hFood,8hDrug,8hand8hCosmetic8hAct8hof8h19388hauthorized8hthe8hFDA8hto8hdetermine
8hthe8hsafety8hof8hall8hdrugs8hbefore8hmarketing.8hLater8hamendments8hand8hacts8hhelped8htighten8h
FDA8hcontrol8hand8hensure8hdrug8hsafety.8hThe8hDurham8hHumphrey8hAmendment8hdefines8hthe8h
kinds8hof8hdrugs8hthat8hcannot8hbe8hused8hsafely8hwithout8hmedical8hsupervision8hand8hrestricts8hth
eir8hsale8hto8hprescription8hby8ha8hlicensed8hpractitioner.8hThe8hControlled8hSubstances8hAct8haddre
sses8honly8hcontrolled8hsubstances8hand8htheir8hcategorization.8hThe8hKefauver8hHarris8hDrug8hAme
ndment8hensures8hdrug8hefficacy8hand8hgreater8hdrug8hsafety.8hDrug8hmanufacturers8hare8hrequired8h
to8hprove8hto8hthe8hFDA8hthe8heffectiveness8hof8htheir8hproducts8hbefore8hmarketing8hthem.
DIF: Cognitive8hLevel:8hKnowledge REF:8hp.8h58hTable8hl.3
OBJ:8 h 5
NAT:8hNCLEX8hClient8hNeeds8hCategory:8hPhysiological8hInte
grity8hTOP:8 h Nursing8hProcess8hStep:8hAssessment
CON:8 h Safety8h|8hPatient8hEducation8h|8hEvidence8h|8hHealth8hCare8hLaw
7. Which8hclassification8hdoes8hmeperidine8h(Demerol)8hfall8hunder?
a. I
b. II
c. III
d. IV
ANS:8 h B
Meperidine8h(Demerol)8his8ha8hSchedule8hII8hdrug;8hit8hhas8ha8hhigh8hpotential8hfor8habuse8hand8hm
ay8hlead8hto8sh evere8hpsychological8hand8hphysical8hdependence.8hSchedule8hI8hdrugs8hhave8hhigh8hp
otential8hfor8habuse8ah nd8hno8hrecognized8hmedical8huse.8hSchedule8hIII8hdrugs8hhave8hsome8hpotent
ial8hfor8habuse.8hUse8hmay8hlead8hto8hlow8hto8hmoderate8hphysical8hdependence8hor8hhigh8hpsychol
ogical8hdependence.8hSchedule8hIV8hdrugs8hhave8hlow8hpotential8hfor8habuse.8hUse8hmay8hlead8hto8h
limited8hphysical8hor8hpsychological8hdependence.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h10
OBJ:8h28hNAT:8 h NCLEX8hClient8hNeeds8hCategory:8hSafe,8hEffectiv
e8hCare8hEnvironment
TOP:8 h Nursing8hProcess8hStep:8hAssessment CON:8 h Patient8hEducation8h|8hAddiction8h|8hPain
8. Which8haction8hwould8hthe8hFDA8htake8hto8hexpedite8hdrug8hdevelopment8hand8happroval8hfor8han8ho
utbreak8hof8hsmallpox?
a. List8hsmallpox8has8ha8hhealth8horphan8hdisease.
b. Omit8hthe8hpreclinical8hresearch8hphase.
c. Extend8hthe8hclinical8hresearch8hphase.
d. Fast8htrack8hthe8hinvestigational8hdrug.
ANS:8h D
Once8hthe8hInvestigational8hNew8hDrug8hApplication8hhas8hbeen8happroved,8hthe8hdrug8hcan8hrecei
ve8hhighest8hpriority8hwithin8hthe8hagency,8hwhich8his8hcalled8hfast8htracking.8hA8hsmallpox8houtbr
eak8hwould8hbecome8ha8hpriority8hconcern8hin8hthe8hworld.8hOrphan8hdiseases8hare8hnot8hresearche
d8hin8ha8hpriority8hmanner.8hPreclinical8hresearch8his8hnot8homitted.8hExtending8hany8hphase8hof8hth
e8hresearch8hwould8hmean8ha8hlonger8htime8hto8hdevelop8ha8hvaccine.8hThe8hFDA8hmust8hensure8hthat8h
all8hphases8hof8hthe8hpreclinical8hand8hclinical8hresearch8hphase8hhave8hbeen8hcompleted8hin8ha8hsafe8h
manner.
DIF: Cognitive8hLevel:8hKnowledge REF:8h8h8hp.8h7 OBJ:8 h 5
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter8h01:8hDrug8hDefinitions,8hStandards,8hand8hInformation8hSources8hWillihn
ganz:8hClayton’s8hBasic8hPharmacology8hfor8hNurses,8h19th8hEdition
MULTIPLE8hCHOIC
E
1. Which8hname8hidentifies8ha8hdrug8hlisted8hby8hthe8hUS8hFoo
d8hand8hDrug8hAdministration8h(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS:8h C
The8hofficial8hname8his8hthe8 h name8hunder8hwhich8ha8hdrug8his8
hlisted8hby8hthe8hFDA.8hThe8hbrand8hname,8hor8htrademark,8his8ht
he8hname8hgiven8hto8ha8hdrug8hby8hits8hmanufacturer.8hThe8hnon
proprietary,8hor8hgeneric,8hname8his8hprovided8hby8hthe8hUnited
8hStates8hAdopted8hNames8hCouncil.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h9
OBJ:8h1NAT:8hNCLEX8hClient8hNeeds8hCategory:8hSafe,8hEffective
8hCare8hEnvironment8hTOP:8 h Nursing8hProcess8hStep:8hAssessment
CON:8
hPatient8hEducation
2. Which8hsource8hcontains8hinformation8hspecific8hto8hnutritional8hsupplements?
a. USP8hDictionary8hof8hUSAN8h &8hInternational8hDrug8hNames
b. Natural8hMedicines8hComprehensive8hDatabase
c. United8hStates8hPharmacopoeia/National8hFormulary8h(USP8hNF)
d. Drug8hInteraction8hFacts
ANS:8h C
United8hStates8hPharmacopoeia/National8hFormulary8hcontains8hinformation8hspecific8hto8hnutriti
onal8hsupplements.8hUSP8hDictionary8hof8hUSAN8h&8hInternational8hDrug8hNames8his8ha8hcompilat
ion8hof8hdrug8hnames,8hpronunciation8hguide,8hand8hpossible8hfuture8hFDA8happroved8hdrugs;8hit8hd
oes8hnot8hinclude8hnutritional8hsupplements.8hNatural8hMedicines8hComprehensive8hDatabase8hc
ontains
evidence-
based8hinformation8hon8hherbal8hmedicines8hand8hherbal8hcombination8hproducts;8hit8hdoes8hnot8hincl
ude8hinformation8hspecific8hto8hnutritional8hsupplements.8hDrug8hInteraction8hFacts8hcontains8hco
mprehensive8hinformation8hon8hdrug8hinteraction8hfacts;8hit8hdoes8hnot8hinclude8hnutritional8hsupp
lements.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h4
OBJ:8h38hNAT:8 h NCLEX8hClient8hNeeds8hCategory:8hPhysiological8
hIntegrity
TOP:8 h Nursing8hProcess8hStep:8hAssessment CON:8 h Nutrition8h|8hPatient8hEducation
3. Which8hdrug8hreference8hcontains8hdrug8hmonographs8hthat8hdescribe8hall8hdrugs8hin8ha8htherapeutic8hclass?
a. Drug8hFacts8hand8hComparisons
,Test8hBank8hFor8hClayton’s8hBasic8hPharmacology8hfor8hNurses8h19th8 3
hEdition
b. Drug8hInteraction8hFacts
c. Handbook8hon8hInjectable8hDrugs
d. Martindale—The8hComplete8hDrug8hReference
ANS:8 h A
Drug8hFacts8hand8hComparisons8hcontains8hdrug8hmonographs8hthat8hdescribe8hall8hdrug
s8hin8ha8htherapeutic8hclass.8hMonographs8hare8hformatted8has8htables8hto8hallow8hcompariso
n8hof8hsimilar8ph roducts,8hbrand8hnames,8hmanufacturers,8hcost8hindices,8hand8havailable8hd
osage8hforms8hOnline8hversion8his8havailable.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h48hTable8h1.2
OBJ:8h8h8 h 3 NAT:8 h NCLEX8hClient8hNeeds8hCategory:8hPhysiological8hIntegrity
TOP:8 h Nursing8hProcess8hStep:8hAssessment CON:8 h Safety8h|8hPatient8hEducation8h|8hClinical8hJudgment
4. Which8hdrug8hreference8hcontains8hmonographs8habout8h virtually8hevery8hsingle-
entity8hdrug8havailable8hin8hthe8hUnited8hStates8hand8hdescribes8htherapeutic8huses8hof8hdrugs,8hincl
uding8happroved8hand8hunapproved8huses?
a. Martindale:8hThe8hComplete8hDrug8hReference
b. AHFS8hDrug8hInformation
c. Drug8hReference
d. Drug8hFacts8hand8hComparisons
ANS:8 h B
AHFS8hDrug8hInformation8hcontains8hmonographs8habout8hvirtually8hevery8hsingle-
entity8hdrug8havailable8hin8hthe8hUnited8hStates8hand8hdescribes8htherapeutic8huses8hof8hdrugs,8hinclu
ding8happroved8hand8hunapproved8huses.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h48hTable8h1.2
OBJ:8h8h8 h 3 NAT:8 h NCLEX8hClient8hNeeds8hCategory:8hPhysiological8hIntegrity
TOP:8 h Nursing8hProcess8hStep:8hPlanning CON:8 h Safety8h|8hPatient8hEducation8h|8hClinical8hJudgment
5. Which8honline8hdrug8hreference8hmakes8havailable8hto8hhealthcare8hproviders8hand8hthe8hpubli
c8ha8hstandard,8hcomprehensive,8hup-to-
date8hlook8hup8hand8hdownloadable8hresource8habout8hmedicines?
a. American8hDrug8hIndex
b. American8hHospital8hFormulary
c. DailyMed
d. Drug8hReference
ANS:8h C
DailyMed8hmakes8havailable8hto8hhealthcare8hproviders8hand8hthe8hpublic8ha8hstandard,8hcomprehe
nsive,8hup-to-
date8hlook8hup8hand8hdownloadable8hresource8habout8hmedicines.8hThe8hAmerican8hDrug8hIndex8hi
s8hnot8happropriate8hfor8hpatient8huse.8hThe8hAmerican8hHospital8hFormulary8his8hnot8happropriate
8hfor8hpatient8h use.8hThe8hdrug8hreference8h is8hnot8happropriate8hfor8hpatient8h use.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h38h|8hp.8h4
OBJ:8h38hNAT:8 h NCLEX8hClient8hNeeds8hCategory:8hPhysiological8
hIntegrity
TOP:8 h Nursing8hProcess8hStep:8hImplementation
CON:8 h Safety8h|8hPatient8hEducation8h|8hClinical8hJudgment
6. Which8hlegislation8hauthorizes8hthe8hFDA8hto8hdetermine8hthe8hsafety8hof8ha8hdrug8hbefore8hits8hmarketing?
a. Federal8hFood,8hDrug,8hand8hCosmetic8hAct8h(1938)
b. Durham8hHumphrey8hAmendment8h(1952)
, Test8hBank8hFor8hClayton’s8hBasic8hPharmacology8hfor8hNurses8h19th8 4
hEdition
c. Controlled8hSubstances8hAct8h(1970)
d. Kefauver8hHarris8hDrug8hAmendment8h(1962)
ANS:8 h A
The8hFederal8hFood,8hDrug,8hand8hCosmetic8hAct8hof8h19388hauthorized8hthe8hFDA8hto8hdetermine
8hthe8hsafety8hof8hall8hdrugs8hbefore8hmarketing.8hLater8hamendments8hand8hacts8hhelped8htighten8h
FDA8hcontrol8hand8hensure8hdrug8hsafety.8hThe8hDurham8hHumphrey8hAmendment8hdefines8hthe8h
kinds8hof8hdrugs8hthat8hcannot8hbe8hused8hsafely8hwithout8hmedical8hsupervision8hand8hrestricts8hth
eir8hsale8hto8hprescription8hby8ha8hlicensed8hpractitioner.8hThe8hControlled8hSubstances8hAct8haddre
sses8honly8hcontrolled8hsubstances8hand8htheir8hcategorization.8hThe8hKefauver8hHarris8hDrug8hAme
ndment8hensures8hdrug8hefficacy8hand8hgreater8hdrug8hsafety.8hDrug8hmanufacturers8hare8hrequired8h
to8hprove8hto8hthe8hFDA8hthe8heffectiveness8hof8htheir8hproducts8hbefore8hmarketing8hthem.
DIF: Cognitive8hLevel:8hKnowledge REF:8hp.8h58hTable8hl.3
OBJ:8 h 5
NAT:8hNCLEX8hClient8hNeeds8hCategory:8hPhysiological8hInte
grity8hTOP:8 h Nursing8hProcess8hStep:8hAssessment
CON:8 h Safety8h|8hPatient8hEducation8h|8hEvidence8h|8hHealth8hCare8hLaw
7. Which8hclassification8hdoes8hmeperidine8h(Demerol)8hfall8hunder?
a. I
b. II
c. III
d. IV
ANS:8 h B
Meperidine8h(Demerol)8his8ha8hSchedule8hII8hdrug;8hit8hhas8ha8hhigh8hpotential8hfor8habuse8hand8hm
ay8hlead8hto8sh evere8hpsychological8hand8hphysical8hdependence.8hSchedule8hI8hdrugs8hhave8hhigh8hp
otential8hfor8habuse8ah nd8hno8hrecognized8hmedical8huse.8hSchedule8hIII8hdrugs8hhave8hsome8hpotent
ial8hfor8habuse.8hUse8hmay8hlead8hto8hlow8hto8hmoderate8hphysical8hdependence8hor8hhigh8hpsychol
ogical8hdependence.8hSchedule8hIV8hdrugs8hhave8hlow8hpotential8hfor8habuse.8hUse8hmay8hlead8hto8h
limited8hphysical8hor8hpsychological8hdependence.
DIF: Cognitive8hLevel:8hKnowledge REF:8 h p.8h10
OBJ:8h28hNAT:8 h NCLEX8hClient8hNeeds8hCategory:8hSafe,8hEffectiv
e8hCare8hEnvironment
TOP:8 h Nursing8hProcess8hStep:8hAssessment CON:8 h Patient8hEducation8h|8hAddiction8h|8hPain
8. Which8haction8hwould8hthe8hFDA8htake8hto8hexpedite8hdrug8hdevelopment8hand8happroval8hfor8han8ho
utbreak8hof8hsmallpox?
a. List8hsmallpox8has8ha8hhealth8horphan8hdisease.
b. Omit8hthe8hpreclinical8hresearch8hphase.
c. Extend8hthe8hclinical8hresearch8hphase.
d. Fast8htrack8hthe8hinvestigational8hdrug.
ANS:8h D
Once8hthe8hInvestigational8hNew8hDrug8hApplication8hhas8hbeen8happroved,8hthe8hdrug8hcan8hrecei
ve8hhighest8hpriority8hwithin8hthe8hagency,8hwhich8his8hcalled8hfast8htracking.8hA8hsmallpox8houtbr
eak8hwould8hbecome8ha8hpriority8hconcern8hin8hthe8hworld.8hOrphan8hdiseases8hare8hnot8hresearche
d8hin8ha8hpriority8hmanner.8hPreclinical8hresearch8his8hnot8homitted.8hExtending8hany8hphase8hof8hth
e8hresearch8hwould8hmean8ha8hlonger8htime8hto8hdevelop8ha8hvaccine.8hThe8hFDA8hmust8hensure8hthat8h
all8hphases8hof8hthe8hpreclinical8hand8hclinical8hresearch8hphase8hhave8hbeen8hcompleted8hin8ha8hsafe8h
manner.
DIF: Cognitive8hLevel:8hKnowledge REF:8h8h8hp.8h7 OBJ:8 h 5